Significant effect of decreased weight and HbA1c by oral semaglutide (Rybelsus) for Type 2 Diabetes (T2D) patient

Bando H, Kato Y, Yamashita H, Kawata T and Ogura K

Published on: 2023-12-31

Abstract

Background

Authors et al. have continued clinical diabetic research for years. Oral semaglutide (Rybelsus) has been applied to type 2 diabetes (T2D).

Case Presentation

Case is 53-year-old male T2D patient for 10 years. The HbA1c was increased to 7.2% in January 2023, and then Rybelsus was increased from 7mg to 14mg/day. HbA1c was decreased to 5.8% in Dec 2023 with 9kg weight reduction.

Discussion and conclusion

The blood concentration of semaglutide is determined by the fasting time after taking the drug in the morning. He carefully adjusted fasting time in 15-minute increments to ensure gradually rising its blood concentration.